These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 20819013

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS.
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [Abstract] [Full Text] [Related]

  • 3. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 4. Knowns and unknowns in the future of multiple sclerosis treatment.
    Stüve O.
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New therapeutic approaches for multiple sclerosis.
    De Jager PL, Hafler DA.
    Annu Rev Med; 2007 Dec; 58():417-32. PubMed ID: 17217332
    [Abstract] [Full Text] [Related]

  • 10. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G, Morrissey S, Le Page E.
    J Neurol Sci; 2004 Aug 15; 223(1):35-9. PubMed ID: 15261558
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC, Meuth SG, Bittner S, Kleinschnitz C, Kieseier BC, Wiendl H.
    BioDrugs; 2010 Aug 01; 24(4):249-74. PubMed ID: 20623991
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Emerging therapies in multiple sclerosis.
    Farrell R, Heaney D, Giovannoni G.
    Expert Opin Emerg Drugs; 2005 Nov 01; 10(4):797-816. PubMed ID: 16262563
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MS treatment: new perspectives.
    Comi G, Martino G.
    Clin Neurol Neurosurg; 2006 Mar 01; 108(3):339-45. PubMed ID: 16386359
    [Abstract] [Full Text] [Related]

  • 19. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 20. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments.
    Galimberti D, Bresolin N, Scarpini E.
    Expert Rev Neurother; 2004 May 20; 4(3):439-53. PubMed ID: 15853541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.